CureVac N.V. (CVAC)
Stock Price Chart
Key Info
| Market Cap | 9.27B |
| Revenue (ttm) | 17.38M |
| Net Income (ttm) | -99.87M |
| Shares Out | 177.97M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | 43.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Sep 18, 2020 |
| Last Price | $52.09 |
| Previous Close | $52.90 |
| Change ($) | -0.81 |
| Change (%) | -1.53% |
| Day's Open | 52.13 |
| Day's Range | 51.66 - 53.28 |
| Day's Volume | 470,717 |
| 52-Week Range | 36.15 - 85.00 |
More Stats
| Market Cap | 9.27B |
| Enterprise Value | 9.32B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 177.97M |
| Float | 36.68M |
| EPS (basic) | n/a |
| EPS (diluted) | -0.58 |
| FCF / Share | -0.56 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | n/a |
| Short Ratio | n/a |
| Short % of Float | n/a |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | 43.67 |
| P/FCF Ratio | n/a |
| PS Ratio | 533.42 |
| PB Ratio | n/a |
| Revenue | 17.38M |
| Operating Income | -99.50M |
| Net Income | -99.87M |
| Free Cash Flow | -98.14M |
| Net Cash | -47.01M |
| Net Cash / Share | -0.26 |
| Gross Margin | n/a |
| Operating Margin | n/a |
| Profit Margin | -573.50% |
| FCF Margin | n/a |
| ROA | -51.16% |
| ROE | n/a |
| ROIC | -91.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 |
|---|---|---|
| Revenue | 17.42 | 12.87 |
| Revenue Growth | 35.31% | - |
| Gross Profit | -10.57 | -4.87 |
| Operating Income | -99.50 | -72.82 |
| Net Income | -99.87 | -71.24 |
| Shares Outstanding | 176 | - |
| Earnings Per Share | -137.45 | -98.05 |
| Operating Cash Flow | -86.96 | -74.11 |
| Capital Expenditures | -11.17 | -9.41 |
| Free Cash Flow | -98.14 | -83.52 |
| Cash & Equivalents | 32.14 | 60.63 |
| Total Debt | 79.15 | 0.08 |
| Net Cash / Debt | -47.01 | 60.56 |
| Assets | 131 | 126 |
| Liabilities | 173 | 93.58 |
| Book Value | -42.80 | 32.08 |
Company Profile
Company Details
| Full Name | CureVac N.V. |
| Country | Germany |
| Employees | 484 |
| CEO | Franz-Werner Haas |
Stock Information
| Ticker Symbol | CVAC |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: CVAC |
| IPO Date | August 14, 2020 |
Description
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076